Natera, Inc.(NTRA)今日夜盘交易中股价大涨13.05%，引发市场广泛关注。
消息面上，公司于盘后发布了最新季度财报。此前市场一致预期本季度营收为6.61亿美元，同比增长38.72%，调整后每股亏损0.49美元。值得注意的是，公司此前已将全年营收指引上调至27.4亿至28.2亿美元，显著高于市场预期的26.7亿美元，且前两个季度营收均大幅超出预期，显示出强劲的增长势头。
此外，公司核心产品Signatera近期接连获得欧盟IVDR认证、日本PMDA批准及美国NCCN一类推荐，同时与Aveta Biomics、Eledon等多家生物医药公司达成三期临床合作，持续巩固其在MRD检测领域的领导地位。这些积极进展进一步提振了市场信心，推动股价夜盘大幅走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.